Keep knowledgeable with free updates
Merely signal as much as the Prescribed drugs sector myFT Digest — delivered on to your inbox.
Pfizer has clinched a deal value as much as $10bn to purchase weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo Nordisk tried to gatecrash its earlier bid.
After a week-long bidding struggle which was prompted by Novo submitting an unsolicited provide for Metsera in late October, the weight-loss biotech stated late on Friday that it had opted to pursue a cope with Pfizer due to antitrust issues raised by the US competitors watchdog over Novo’s provide.
Pfizer’s new deal to purchase Metsera values the biotech at as a lot as $2.7bn greater than an earlier settlement from September. As a part of the deal, Metsera’s shareholders will obtain $65.50 a share in money upfront and an additional $20.65 a share primarily based on sure medical trial milestones being met.
Metsera stated it had obtained a name from the US Federal Commerce Fee warning concerning the uncommon construction of Novo’s deal, main it to conclude that it “presents unacceptably excessive authorized and regulatory dangers”. Novo, alongside Eli Lilly, is among the dominant gamers within the weight-loss drug market with its Ozempic and Wegovy medicines.
The weird two-step construction of Novo’s deal, which supplied to pay Metsera’s shareholders greater than $7bn nearly instantly upon signing by way of a dividend, prompted Pfizer to file lawsuits to dam the acquisition and drew warnings from the FTC that it “could violate” antitrust guidelines.
In a letter to Metsera’s board earlier this week, the FTC stated it may demand “the refund of any monies paid upfront”. Metsera added on Friday that one of many dangers of Novo’s deal was “that the preliminary dividend could by no means be paid or could also be subsequently challenged or rescinded”.
Metsera, which was based simply three years in the past and has 100 workers, has among the many most promising pipelines of experimental weight-loss therapies, together with a longer-acting, month-to-month injectable, a weight-loss capsule and medicines utilizing a special chemical mechanism, Amylin.
The takeover battle drew backwards and forwards jousts from Pfizer and Novo. Below its new chief government Maziar Mike Doustdar, Novo is making an attempt to reverse a 50 per cent share value slide as buyers concern it’s being crushed by Eli Lilly within the weight-loss drug race. In the meantime, Pfizer is making an attempt to purchase a foothold within the profitable market after its medication being developed in-house flopped in medical trials earlier this yr.
At an look on the White Home asserting a drug pricing deal on Thursday, Doustdar stated Novo had outbid Pfizer and goaded its US rival to spice up its bid.
“Our message to Pfizer is: in the event that they wish to purchase the corporate, then put your hand in your pocket and bid increased, it’s a free market,” he stated, including that “this has nothing to do with the FTC”.
On an earnings name earlier this week, Pfizer chief government Albert Bourla criticised Novo’s Metsera bid. “It’s an unlawful assault by a overseas firm to do an finish run round antitrust legal guidelines, benefiting from the federal government shutdown.”
